Saint Simeon Marketing and Investments

Saint Simeon Marketing and Investments is an Israeli-based private investment firm and holding company that operates as a strategic vehicle for the Eyal Ofer Group. The firm is primarily recognized for its significant ownership stake and long-term support of MediWound, a biopharmaceutical company focused on enzymatic therapeutics for tissue regeneration. Through its portfolio, Saint Simeon is involved in the advancement of treatments for severe burns and chronic wound care, including the FDA-approved product NexoBrid. The company plays a crucial role in the financial and strategic management of its life science interests, focusing on innovative medical technologies. It maintains a low public profile while exerting significant influence on the Israeli biotechnology landscape.